AstraZeneca to Buy Actavis Respiratory Drugs

Feb 06, 2015


AstraZeneca will buy Actavis' branded respiratory drug business in the U.S. and Canada for an initial $600 million, plus an additional $100 million.

The deal is expected to complete by the end of March.

Respiratory is a key therapeutic area for AstraZeneca; the drugmaker has predicted a 75 percent jump in annual sales to $45 billion by 2023.

Last July, AstraZeneca acquired the rights to a portfolio of inhaled drugs from Barcelona-based Almirall for $875 million up front, in a deal worth up to $2.1 billion total, building its respiratory drug portfolio.

Read the Reuters press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments